Previously, COX-2 overexpression has been described in multiple human cancers including skin, bone, oesophageal, breast, lung, pancreatic, colon, cervical, prostate and bladder cancer, and is inversely associated with patient survival (8). This evidence concerns the gene PTGS2 and urinary bladder carcinoma.